Lenacapavir Injection Offers Breakthrough in HIV Prevention

The twice-yearly injectable drug shows 96% effectiveness in reducing HIV risk, though affordability and resistance concerns remain.

Lenacapavir, a new injectable drug administered every six months, has demonstrated 96% effectiveness in preventing HIV infection in Phase 3 trials.
The drug offers a more convenient alternative to daily oral PrEP medications like Truvada, which can carry social stigma in some communities.
Studies show Lenacapavir is particularly promising for high-risk populations, including women in sub-Saharan Africa, where HIV prevalence is high.
Concerns persist about the drug's affordability, with its current annual cost in the U.S. reaching $42,000, making accessibility in low-income regions uncertain.
Experts caution about potential resistance development if doses are missed, suggesting careful management and possible follow-up with other treatments like Truvada.